President Trump signed an executive order on Saturday that could change the trajectory of thousands of lives. Standing in the Oval Office alongside conservative podcaster Joe Rogan and decorated Navy SEAL Marcus Luttrell — whose 2005 survival in Afghanistan became the basis of Lone Survivor — Trump declared the order would “ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life.” The directive instructs the FDA Commissioner to fast-track priority review of psychedelic therapies that have received Breakthrough Therapy designations, commits $50 million in federal match funding to states building ibogaine research programs, clears the way for the first-ever clinical trials of ibogaine on U.S. soil, and expands patient access through Trump’s own Right to Try framework. Ibogaine stays on Schedule I for now. But the runway for relief has never been wider.

This is not experimental sentimentality. This is overdue policy applied to a crisis Washington has let fester for decades.

For years the FDA treated ibogaine as though it were synthesized in a rogue chemistry lab rather than extracted from a plant whose healing applications span centuries. Veterans carrying PTSD and traumatic brain injuries have quietly flown to unregulated clinics in Mexico for treatment American doctors cannot legally provide at home. My brother is a retired Special Forces Green Beret. Several of his close friends, men who look like your neighbors coaching Little League on a Saturday morning, carry wounds that refuse to stay quiet. Last year I attended a fundraiser for psychedelic treatments in Coronado, headlined by........

© Townhall